key: cord-0027839-oqx55o2j
authors: Sookaromdee, Pathum; Wiwanitkit, Viroj
title: “Large-vessel vasculitis following the Pfizer-BioNTech COVID-19 vaccine”: comment
date: 2022-02-27
journal: Intern Emerg Med
DOI: 10.1007/s11739-022-02946-6
sha: 7953d3af56146e6bbe3871c4f44e2d380cab1e03
doc_id: 27839
cord_uid: oqx55o2j

nan

We would like to share ideas on the publication "Large-vessel vasculitis following the Pfizer-BioNTech COVID-19 vaccine [1] ". Gilio and De Stefano mentioned that "The pathogenesis of post-vaccination vasculitis remains unclear. To our knowledge, this is the first report of large vessel vasculitis following by BNT162b2 vaccination…… [1] ." We concur that COVID-19 vaccination can have negative consequences, with large-vessel vasculitis being one example. However, as Gilio and De Stefano pointed out, no clear pathophysiology has been provided in this case. Atypical immunological responses are frequently cited as a source of several of the COVID-19 vaccine's side effects. There is also no information on the patient's immunological status or vascular health prior to vaccination. We should be aware that large-vessel vasculitis in a COVID-19 vaccination recipient could be caused by an underlying disease or a concomitant medical issue. Dengue fever could emerge in a vaccine recipient as an example of a concomitant medical illness [2] . Dengue is also a possible cause of large vessel vasculitis [3] .

Author contributions PS: substantial contributions to study conception and design, substantial contributions to acquisition of data, substantial contributions to analysis and interpretation of data, drafting the article or revising it critically for important intellectual content, final approval of the version of the article to be published. VW: substantial contributions to study conception and design, substantial contributions to acquisition of data, substantial contributions to analysis and interpretation of data, drafting the article or revising it critically for important intellectual content, final approval of the version of the article to be published.

The author(s) declare that they have no conflict of interest.

This is a correspondence on published article and doese not involve with any human or animal subjects. Ethical approval and informed consent are not required.

Large-vessel vasculitis following the Pfizer-BioNTech COVID-19 vaccine

Dengue after COVID-19 vaccination: possible and might be missed

Expanded dengue syndrome with small-medium-vessel vasculitis: a case report